Chai Discovery vs Figma

Side-by-side comparison of AI visibility scores, market position, and capabilities

Figma leads in AI visibility (99 vs 69)
Chai Discovery logo

Chai Discovery

ChallengerHealthcare Tech

AI Molecular Discovery

AI molecular discovery unicorn ($1.3B valuation). 100x improvement in de novo antibody design success. Backed by OpenAI. Eli Lilly partnership. Founded 2023, SF. $225M+ raised.

AI VisibilityBeta
Overall Score
B69
Category Rank
#1 of 1
AI Consensus
77%
Trend
up
Per Platform
ChatGPT
74
Perplexity
74
Gemini
73

About

Chai Discovery is an AI-driven molecular discovery company founded in 2024 and headquartered in San Francisco. The company was spun out of research conducted by scientists with backgrounds at leading computational biology and AI organizations, with the founding mission of applying the latest advances in generative AI to accelerate drug discovery — particularly the historically difficult challenge of designing novel antibodies and small molecules from scratch rather than optimizing known chemical scaffolds.\n\nChai's core technology is a foundation model for molecular structure prediction and de novo design that operates across proteins, small molecules, nucleic acids, and their complexes. The company's flagship research achievement is a reported 100-fold improvement in de novo antibody design success rates, enabling the generation of functional antibody candidates without requiring extensive experimental screening campaigns. Chai Discovery has established a research partnership with Eli Lilly, one of the world's largest pharmaceutical companies, to apply its platform to therapeutic target programs. The company is backed by OpenAI, reflecting the deep connection between large-scale AI modeling techniques and the biological sequence-structure-function prediction task.\n\nChai Discovery reached a $1.3 billion valuation within its first year of operation, an exceptionally rapid ascent reflecting the strategic premium investors place on AI-native molecular discovery platforms. The company operates at the intersection of structural biology, generative AI, and therapeutic development, competing with platforms like Isomorphic Labs, Recursion, and Insilico Medicine in the race to demonstrate AI-designed drugs in human clinical trials.

Full profile
Figma logo

Figma

LeaderDesign & Creative Tools

Design & Collaboration

Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.

AI VisibilityBeta
Overall Score
A99
Category Rank
#1 of 1
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
90
Perplexity
99
Gemini
97

About

Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.

Full profile

AI Visibility Head-to-Head

69
Overall Score
99
#1
Category Rank
#1
77
AI Consensus
77
up
Trend
stable
74
ChatGPT
90
74
Perplexity
99
73
Gemini
97
65
Claude
94
70
Grok
99

Capabilities & Ecosystem

Capabilities

Only Chai Discovery
AI Molecular Discovery
Only Figma
Design & Collaboration

Integrations

Figma is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.